Novartis pivotal data show children and adolescents with relapsing MS had an 82% lower relapse rate with fingolimod vs. interferon beta-1a

Novartis announced results from the Phase III PARADIGMS study, investigating the safety and efficacy of fingolimod vs. interferon beta-1a, in children and adolescents (ages 10 to <18) with relapsing multiple sclerosis (MS).

• Source: Prnewswire
• 668
• November 1, 2017